Jean-Paul Clozel presented at the 41st J.P. Morgan Healthcare Conference on January 9, 2023
Idorsia initiates Phase 3 program with cenerimod for the treatment of patients with SLE
The Lancet and AHA late-breaking science session reports significant and sustained effect of aprocitentan on lowering blood pressure for patients with resistant hypertension
Europe’s first dual orexin receptor antagonist – QUVIVIQTM (daridorexant) – granted approval
QUVIVIQ® (daridorexant) is now available in the US for adults
living with insomnia
PIVLAZTM (clazosentan) – Idorsia’s
first commercial product – now
available for patients in Japan
The purpose of Idorsia is to discover, develop and bring more, innovative medicines to patients.
Idorsia’s success depends on its people.
Idorsia's development compounds target a number of different diseases.
| 09 Jan 2023 | |
| 20 Dec 2022 | |
| 15 Dec 2022 |
| Event | When |
|
Full-Year 2022 Financial Results reporting* |
February 7, 2023
|
|
First Quarter 2023 Financial Results reporting* |
April 25, 2023
|
|
Annual General Meeting of Shareholders |
May 4, 2023 |
|
Half-Year 2023 Financial Results reporting* |
July 25, 2023 |
*We will be in a silent period for 10 days ahead of the financial reporting.
